CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

US biopharma Viking Therapeutics developing therapies for metabolic and endocrine disorders, closed Tuesday’s trading 5% ...

Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735: San Diego Wednesday, March 12, 2025, 17:00 Hrs [IST] Viking Therapeutic ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

This long-term agreement will help support the commercialization of VK2735.

CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...